Obesity Surgery

, Volume 28, Issue 10, pp 3131–3135 | Cite as

Impact of Weight Regain on the Evolution of Non-alcoholic Fatty Liver Disease After Roux-en-Y Gastric Bypass: a 3-Year Follow-up

  • Laísa Simakawa Jimenez
  • Fábio Henrique Mendonça Chaim
  • Felipe David Mendonça Chaim
  • Murillo Pimentel Utrini
  • Martinho Antonio Gestic
  • Elinton Adami Chaim
  • Everton CazzoEmail author
Original Contributions



The influence of post-surgical weight regain on the course of non-alcoholic fatty liver disease (NAFLD) is unclear.


To evaluate the influence of weight regain on the NAFLD assessed by means of a non-invasive score after Roux-en-gastric bypass (RYGB) over a 3-year period.


This is a prospective observational cohort study which evaluated individuals who underwent RYGB. Comparisons were made between the periods immediately before surgery and 12, 24, and 36 months following surgery. Liver disease was estimated by means of the NAFLD fibrosis score. Individuals were classified into three categories according to weight regain status: (1) no weight regain, (2) expected weight regain (regain less or equal than 20% of the maximal weight lost), (3) obesity recidivism (regain above 20% of the maximal weight lost).


Of 90 patients analyzed after 3 years of surgery, 35.6% presented obesity recidivism and 28.8% of the expected regain; 35.6% presented no regain. There was no difference in baseline fibrosis score between groups; at 3 years, the score observed in the relapse group was significantly higher than that observed in the other two groups (p = 0.015). The percent variation of the fibrosis score was significantly higher in the recidivism group (+ 11.8 ± 77.2%) than in the expected regain (− 45.6 ± 64.5%) and no regain (− 37.8 ± 63.2%) groups (p = 0.013).


Long-term significant post-RYGB weight regain is associated with a significantly attenuated improvement of NAFLD evaluated by means of liver fibrosis score.


Obesity Bariatric surgery Gastric bypass Fatty liver Weight loss 


Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Statement of Informed Consent

Informed consent was obtained from all individual participants included in the study.

Statement of Human and Animal Rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.


  1. 1.
    World Health Organization. Global status report on noncommunicable diseases 2014. Geneva: WHO; 2014. p. 1–298.Google Scholar
  2. 2.
    Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.CrossRefPubMedGoogle Scholar
  3. 3.
    Younossi ZM, Blissett D, Blissett R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64(5):1577–86.CrossRefPubMedGoogle Scholar
  4. 4.
    Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357(8):753–61.CrossRefPubMedGoogle Scholar
  5. 5.
    Sjöholm K, Sjöström E, Carlsson LM, et al. Weight change-adjusted effects of gastric bypass surgery on glucose metabolism: 2- and 10-year results from the Swedish Obese Subjects (SOS) study. Diabetes Care. 2016;39(4):625–31.CrossRefPubMedGoogle Scholar
  6. 6.
    Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366(17):1567–76.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Cazzo E, Gestic MA, Utrini MP, et al. Control of hypertension after roux-en-y gastric bypass among obese diabetic patients. Arq Gastroenterol. 2014;51(1):21–4.CrossRefPubMedGoogle Scholar
  8. 8.
    Bower G, Toma T, Harling L, et al. Bariatric surgery and non-alcoholic fatty liver disease: a systematic review of liver biochemistry and histology. Obes Surg. 2015;25(12):2280–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Mummadi RR, Kasturi KS, Chennareddygari S, et al. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2008;6(12):1396–402.CrossRefPubMedGoogle Scholar
  10. 10.
    Cazzo E, Pareja JC, Chaim EA. Nonalcoholic fatty liver disease and bariatric surgery: a comprehensive review. Sao Paulo Med J. 2017;135(3):277–95.CrossRefPubMedGoogle Scholar
  11. 11.
    Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, et al. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev. 2010;(1):CD007340.Google Scholar
  12. 12.
    Taitano AA, Markow M, Finan JE, et al. Bariatric surgery improves histological features of nonalcoholic fatty liver disease and liver fibrosis. J Gastrointest Surg. 2015;19(3):429–36.CrossRefPubMedGoogle Scholar
  13. 13.
    Cazzo E, Jimenez LS, Pareja JC, et al. Effect of Roux-en-Y gastric bypass on nonalcoholic fatty liver disease evaluated through NAFLD fibrosis score: a prospective study. Obes Surg. 2015;25(6):982–5.CrossRefPubMedGoogle Scholar
  14. 14.
    Magro DO, Geloneze B, Delfini R, et al. Long-term weight regain after gastric bypass: a 5-year prospective study. Obes Surg. 2008;18(6):648–51.CrossRefPubMedGoogle Scholar
  15. 15.
    Maleckas A, Gudaitytė R, Petereit R, et al. Weight regain after gastric bypass: etiology and treatment options. Gland Surg. 2016;5(6):617–24.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    National Institutes of Health. Gastrointestinal surgery for severe obesity: National Institutes of Health Consensus Development Conference statement. Am J Clin Nutr. 1992;55(2 Suppl):615S–9S.Google Scholar
  17. 17.
    Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846–54.CrossRefPubMedGoogle Scholar
  18. 18.
    Berti LV, Campos J, Ramos A, et al. Position of the SBCBM: nomenclature and definition of outcomes of bariatric and metabolic surgery. Arq Bras Cir Dig. 2015;28(Suppl 1):2.CrossRefPubMedGoogle Scholar
  19. 19.
    Sasaki A, Nitta H, Otsuka K, et al. Bariatric surgery and non-alcoholic fatty liver disease: current and potential future treatments. Front Endocrinol (Lausanne). 2014;5:164.Google Scholar
  20. 20.
    DiGiorgi M, Rosen DJ, Choi JJ, et al. Re-emergence of diabetes after gastric bypass in patients with mid- to long-term follow-up. Surg Obes Relat Dis. 2010;6(3):249–53.CrossRefPubMedGoogle Scholar
  21. 21.
    Santo MA, Riccioppo D, Pajecki D, et al. Weight regain after gastric bypass: influence of gut hormones. Obes Surg. 2016;26(5):919–25.CrossRefPubMedGoogle Scholar
  22. 22.
    Alvarez V, Carrasco F, Cuevas A, et al. Mechanisms of long-term weight regain in patients undergoing sleeve gastrectomy. Nutrition. 2016;32(3):303–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Burza MA, Romeo S, Kotronen A, et al. Long-term effect of bariatric surgery on liver enzymes in the Swedish Obese Subjects (SOS) study. PLoS One. 2013;8(3):e60495.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Simo KA, McKillop IH, McMillan MT, et al. Does a calculated “NAFLD fibrosis score” reliably negate the need for liver biopsy in patients undergoing bariatric surgery? Obes Surg. 2014;24(1):15–21.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Laísa Simakawa Jimenez
    • 1
  • Fábio Henrique Mendonça Chaim
    • 1
  • Felipe David Mendonça Chaim
    • 1
  • Murillo Pimentel Utrini
    • 1
  • Martinho Antonio Gestic
    • 1
  • Elinton Adami Chaim
    • 1
  • Everton Cazzo
    • 1
    Email author
  1. 1.Department of Surgery, Faculty of Medical SciencesState University of Campinas (UNICAMP)CampinasBrazil

Personalised recommendations